See more : Rossi Residencial S.A. (RSID3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Abingdon Health Plc (ABDXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abingdon Health Plc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Alcoa Corporation (AAI.AX) Income Statement Analysis – Financial Results
- Planet, Inc. (2391.T) Income Statement Analysis – Financial Results
- GDH Supertime Group Company Limited (001338.SZ) Income Statement Analysis – Financial Results
- Tracxn Technologies Limited (TRACXN.BO) Income Statement Analysis – Financial Results
- Aegis Logistics Limited (AEGISLOG.BO) Income Statement Analysis – Financial Results
Abingdon Health Plc (ABDXF)
About Abingdon Health Plc
Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices worldwide. The company offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; PCRD and PCRD FLEX, nucleic acid lateral flow tests used for rapid readouts post isothermal amplification; Abingdon Simply Test, a range of self-tests; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. It also provides AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. In addition, the company provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. Further, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.14M | 4.05M | 2.84M | 11.62M | 5.24M | 2.28M | 2.27M |
| Cost of Revenue | 2.46M | 1.97M | 8.06M | 8.22M | 1.18M | 844.53K | 924.61K |
| Gross Profit | 3.68M | 2.08M | -5.23M | 3.39M | 4.06M | 1.43M | 1.34M |
| Gross Profit Ratio | 59.97% | 51.30% | -184.44% | 29.21% | 77.49% | 62.92% | 59.24% |
| Research & Development | 0.00 | 0.00 | 182.00K | 503.00K | 854.00K | 210.73K | 285.04K |
| General & Administrative | 5.07M | 5.22M | 6.65M | 7.55M | 3.37M | 3.02M | 0.00 |
| Selling & Marketing | 0.00 | 28.00K | 49.00K | 864.00K | 598.03K | -349.88K | 0.00 |
| SG&A | 5.07M | 5.25M | 6.69M | 8.41M | 3.97M | 2.67M | 5.76M |
| Other Expenses | -18.00K | 443.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.05M | 5.25M | 6.88M | 8.91M | 3.97M | 2.88M | 6.05M |
| Cost & Expenses | 7.51M | 7.63M | 14.94M | 17.14M | 5.14M | 3.73M | 6.97M |
| Interest Income | 31.00K | 89.00K | 4.00K | 0.00 | 1.62K | 3.48K | 8.68K |
| Interest Expense | 57.00K | 75.00K | 69.00K | 234.00K | 64.35K | 22.43K | 4.39M |
| Depreciation & Amortization | 426.00K | 774.00K | 759.00K | 8.83M | 749.00K | 4.12M | 289.15K |
| EBITDA | -916.00K | -3.17M | -19.89M | -4.77M | 810.00K | -1.10M | -4.02M |
| EBITDA Ratio | -14.93% | -78.44% | -369.24% | -41.07% | 13.05% | -51.01% | -177.33% |
| Operating Income | -1.37M | -3.59M | -12.11M | -5.52M | 91.73K | -1.45M | -4.70M |
| Operating Income Ratio | -22.38% | -88.70% | -426.98% | -47.51% | 1.75% | -63.71% | -207.34% |
| Total Other Income/Expenses | -26.00K | 14.00K | -65.00K | -234.00K | -63.00K | -18.96K | 7.64M |
| Income Before Tax | -1.40M | -3.57M | -21.69M | -7.05M | -3.50M | -1.47M | 2.93M |
| Income Before Tax Ratio | -22.80% | -88.36% | -764.90% | -60.72% | -66.85% | -64.54% | 129.33% |
| Income Tax Expense | -128.00K | -105.00K | -423.00K | -81.00K | -126.00K | -209.66K | -535.53K |
| Net Income | -1.27M | -3.47M | -21.26M | -6.97M | -3.37M | -1.26M | 3.47M |
| Net Income Ratio | -20.72% | -85.76% | -749.98% | -60.02% | -64.44% | -55.33% | 152.95% |
| EPS | 0.00 | -0.01 | -0.07 | -0.07 | -0.04 | -0.01 | 0.04 |
| EPS Diluted | 0.00 | -0.01 | -0.07 | -0.07 | -0.04 | -0.01 | 0.04 |
| Weighted Avg Shares Out | 302.62M | 304.03M | 291.62M | 95.98M | 95.98M | 95.98M | 95.98M |
| Weighted Avg Shares Out (Dil) | 304.74M | 304.03M | 291.62M | 95.98M | 95.98M | 95.98M | 95.98M |
Source: https://incomestatements.info
Category: Stock Reports